• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

再感染、复发还是 COVID-19 的延迟表现?病例系列和文献复习。

Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature.

机构信息

Internal Medicine Department, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia.

Internal Medicine Department, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia.

出版信息

J Infect Public Health. 2021 Apr;14(4):474-477. doi: 10.1016/j.jiph.2021.01.002. Epub 2021 Jan 14.

DOI:10.1016/j.jiph.2021.01.002
PMID:33743368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834000/
Abstract

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-cov-2), first described in December 2019, has now infected more than 28 million cases with almost one million deaths. Reinfection is not definitely established however disease recurrence is increasingly reported.

CASES PRESENTATION

Four patients presented with a second episode of coronavirus disease 2019 (COVID-19) occurring 27-85 following their first illness. The initial episode was mild or asymptomatic while the second attack was severe requiring hospital admission. All four patients had a SARS-CoV-2 PCR test positive in the second episode. The chest-X-ray and/or computerized tomography (CT) scan showed bilateral alveolar shadows. Furthermore, the inflammatory markers were raised in the four patients. Three patients recovered following treatment with favipravir in addition tocilizumab and/or dexamethasone.

CONCLUSION

Covid19 reinfection Recurrent COVID-19 is increasingly reported. However; other etiologies including superadded infection or pulmonary embolism should be ruled out, particularly if recurrence occurs less than 3 weeks.

摘要

背景

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)于 2019 年 12 月首次描述,现已感染超过 2800 万人,近百万人死亡。然而,目前尚未明确再次感染的情况,但疾病复发的报道越来越多。

病例介绍

4 名患者在首次发病后 27-85 天出现了第二次冠状病毒病 2019(COVID-19)发作。初次发作时症状较轻或无症状,而第二次发作则较为严重,需要住院治疗。这 4 名患者的第二次发作中均检测到 SARS-CoV-2 PCR 阳性。胸部 X 光和/或计算机断层扫描(CT)显示双侧肺泡阴影。此外,这 4 名患者的炎症标志物均升高。除了托珠单抗和/或地塞米松外,3 名患者还接受了法匹拉韦治疗后康复。

结论

COVID-19 再次感染,COVID-19 复发的报道越来越多。然而,其他病因,包括合并感染或肺栓塞等,应予以排除,特别是如果复发发生在 3 周内。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fcc/7834000/223b2961705d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fcc/7834000/223b2961705d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fcc/7834000/223b2961705d/gr1_lrg.jpg

相似文献

1
Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature.再感染、复发还是 COVID-19 的延迟表现?病例系列和文献复习。
J Infect Public Health. 2021 Apr;14(4):474-477. doi: 10.1016/j.jiph.2021.01.002. Epub 2021 Jan 14.
2
A Patient with Asymptomatic SARS-CoV-2 Infection Who Presented 86 Days Later with COVID-19 Pneumonia Possibly Due to Reinfection with SARS-CoV-2.一名无症状的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染者,86天后出现可能因再次感染SARS-CoV-2导致的新型冠状病毒肺炎(COVID-19)。
Am J Case Rep. 2020 Dec 1;21:e927154. doi: 10.12659/AJCR.927154.
3
Reinfection of SARS-CoV-2 - analysis of 23 cases from the literature.SARS-CoV-2 再感染 - 文献中 23 例分析。
Infect Dis (Lond). 2021 Jul;53(7):479-485. doi: 10.1080/23744235.2021.1905174. Epub 2021 Apr 13.
4
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.在无症状至轻症 COVID-19 感染至少 8 个月后,仍能产生强大的体液和细胞免疫反应,并降低再次感染的风险。
J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27.
5
Clinical and Laboratory Findings in Patients With Potential Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection, May-July 2020.2020 年 5 月至 7 月期间可能发生严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)再感染患者的临床和实验室发现。
Clin Infect Dis. 2021 Dec 16;73(12):2217-2225. doi: 10.1093/cid/ciab148.
6
Clinical Presentation of Cases with SARS-CoV-2 Reinfection/ Reactivation.SARS-CoV-2 再感染/再激活病例的临床表现。
J Assoc Physicians India. 2021 Jan;69(1):16-18.
7
COVID-19 reinfection: a rapid systematic review of case reports and case series.COVID-19 再感染:病例报告和病例系列的快速系统评价。
J Investig Med. 2021 Aug;69(6):1253-1255. doi: 10.1136/jim-2021-001853. Epub 2021 May 18.
8
A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.一例 COVID-19 再感染病例:抗体在 SARS-CoV-2 感染中的作用。
CEN Case Rep. 2022 Nov;11(4):422-427. doi: 10.1007/s13730-022-00697-z. Epub 2022 Mar 9.
9
Proper Assignation of Reactivation in a COVID-19 Recurrence Initially Interpreted as a Reinfection.在最初被解释为再次感染的COVID-19复发中重新激活的正确判定
J Infect Dis. 2021 Sep 1;224(5):788-792. doi: 10.1093/infdis/jiab302.
10
Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases.老年 COVID-19 患者的复发或再发:三例描述。
J Am Geriatr Soc. 2020 Oct;68(10):2179-2183. doi: 10.1111/jgs.16728. Epub 2020 Aug 13.

引用本文的文献

1
Visualization of FDA Adverse Drug Reaction Reports: Development and Usability Study of the VisDrugs Web Server.美国食品药品监督管理局不良药物反应报告的可视化:VisDrugs网络服务器的开发与可用性研究
JMIR Form Res. 2025 Jul 31;9:e71519. doi: 10.2196/71519.
2
Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.奥密克戎变异株激增期间住院的新冠病毒感染复发患者的临床特征
Infect Drug Resist. 2024 Nov 11;17:5011-5015. doi: 10.2147/IDR.S485976. eCollection 2024.
3
A follow-up study on respiratory outcomes, quality of life and performance perception of SARS-CoV-2 primary and reinfection in elite athletes: A 9-month prospective study.

本文引用的文献

1
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.抗严重急性呼吸综合征冠状病毒 2 抗体反应的幅度和动力学及其与疾病严重程度的关系。
Clin Infect Dis. 2021 Jan 27;72(2):301-308. doi: 10.1093/cid/ciaa979.
2
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.无症状或轻症 COVID-19 康复者体内具有强大的 T 细胞免疫。
Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14.
3
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.
一项关于 SARS-CoV-2 原发感染和再感染对精英运动员的呼吸道结局、生活质量和运动表现影响的随访研究:一项 9 个月的前瞻性研究。
Eur J Sport Sci. 2024 Jul;24(7):964-974. doi: 10.1002/ejsc.12109. Epub 2024 Apr 23.
4
Collective and Individual Assessment of the Risk of Death from COVID-19 for the Elderly, 2020-2022.2020 - 2022年老年人因新型冠状病毒肺炎死亡风险的集体与个体评估
China CDC Wkly. 2023 May 5;5(18):407-412. doi: 10.46234/ccdcw2023.077.
5
The Effects of Extrinsic and Intrinsic Factors on Neurogenesis.外在和内在因素对神经发生的影响。
Cells. 2023 Apr 29;12(9):1285. doi: 10.3390/cells12091285.
6
Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.人源相同序列、透明质酸和羟甲香豆素——新型冠状病毒肺炎的新机制与治疗
Mol Biomed. 2022 May 20;3(1):15. doi: 10.1186/s43556-022-00077-0.
7
SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.SARS-CoV-2 再次感染对全球疫苗接种运动的效果构成新挑战:对文献报告病例的系统评价。
Int J Environ Res Public Health. 2021 Oct 19;18(20):11001. doi: 10.3390/ijerph182011001.
8
Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020.印度克什米尔地区在首例本地 COVID-19 病例报告 7 个月后,SARS-CoV-2 特异性 IgG 抗体的血清阳性率:2020 年 10 月至 11 月进行的一项基于人群的血清阳性率调查结果。
BMJ Open. 2021 Sep 23;11(9):e053791. doi: 10.1136/bmjopen-2021-053791.
9
Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals.严重急性呼吸综合征冠状病毒 2 血清阳性个体第二波 2019 冠状病毒病期间出现症状性感染的风险。
Clin Infect Dis. 2022 Mar 9;74(5):893-896. doi: 10.1093/cid/ciab556.
10
Elucidating reasons of COVID-19 re-infection and its management strategies.阐明 COVID-19 再感染的原因及其管理策略。
Diabetes Metab Syndr. 2021 May-Jun;15(3):1001-1006. doi: 10.1016/j.dsx.2021.05.008. Epub 2021 May 7.
2019 年冠状病毒病(COVID-19)通过全基因组测序确认为与严重急性呼吸综合征冠状病毒 2 株系不同的病毒再次感染。
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951. doi: 10.1093/cid/ciaa1275.
4
Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.韩国社区治疗中心中无症状和有症状的 SARS-CoV-2 感染患者的临床病程和分子病毒脱落情况。
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452. doi: 10.1001/jamainternmed.2020.3862.
5
A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19.COVID-19背景下循环阈值临床效用的系统评价
Infect Dis Ther. 2020 Sep;9(3):573-586. doi: 10.1007/s40121-020-00324-3. Epub 2020 Jul 28.
6
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
7
Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results.新型冠状病毒 2019 年是否可能再次感染?解读动态 SARS-CoV-2 检测结果。
Am J Emerg Med. 2021 Jan;39:256.e1-256.e3. doi: 10.1016/j.ajem.2020.06.079. Epub 2020 Jul 4.
8
Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion.抗体转阳的产科患者中严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)RNA 的长时间检测。
Obstet Gynecol. 2020 Oct;136(4):838-841. doi: 10.1097/AOG.0000000000004086.
9
Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?新冠康复后临床复发的 COVID-19 症状:病毒复发、再感染还是炎症反弹?
J Infect. 2020 Nov;81(5):816-846. doi: 10.1016/j.jinf.2020.06.073. Epub 2020 Jun 30.
10
High neutralizing antibody titer in intensive care unit patients with COVID-19.COVID-19 重症监护病房患者的高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.